In Support of Neuroimaging Biomarkers of Treatment Response in First-Episode Schizophrenia
- PMID: 27363555
- PMCID: PMC6071671
- DOI: 10.1176/appi.ajp.2016.16030320
In Support of Neuroimaging Biomarkers of Treatment Response in First-Episode Schizophrenia
Conflict of interest statement
Dr. Malhotra is a consultant to Genomind, Inc, FORUM Pharmaceuticals, and Takeda Pharmaceuticals. Dr. Lencz has been a consultant to Eli Lilly. Dr. Sarpal reports no financial relationships with commercial interests.
Comment in
-
Response to Sarpal et al.: Importance of Neuroimaging Biomarkers for Treatment Development and Clinical Practice.Am J Psychiatry. 2016 Jul 1;173(7):733-4. doi: 10.1176/appi.ajp.2016.16030320r. Am J Psychiatry. 2016. PMID: 27363556 No abstract available.
Comment on
-
A Selective Review of Cerebral Abnormalities in Patients With First-Episode Schizophrenia Before and After Treatment.Am J Psychiatry. 2016 Mar 1;173(3):232-43. doi: 10.1176/appi.ajp.2015.15050641. Epub 2015 Dec 1. Am J Psychiatry. 2016. PMID: 26621570 Review.
References
-
- Gong Q, Lui S, Sweeney JA. Selective Review of Cerebral Abnormalities in Patients With First-Episode Schizophrenia Before and After Treatment. Am J Psychiatry. 2016;173:232–243. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
